Loading
Loading
Metabolic & Body Composition · 50mg
Choose dose
Janoshik-tested · 10 vials per kit
5-Amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied in preclinical research for its metabolic and anti-obesity properties. Research has examined its potential to increase NAD+ availability, upregulate SIRT1 activity, enhance mitochondrial biogenesis, reduce adipocyte lipid storage, and improve insulin sensitivity. Studies have explored applications in obesity and metabolic syndrome models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
5-Amino-1MQ
5-Amino-1-Methylquinolinium
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide. Although not a peptide, it is often studied alongside metabolic research peptides. Originally identified via high-throughput screening at Weill Cornell Medicine and the Nomura Research Institute.
By inhibiting NNMT, 5-Amino-1MQ preserves SAM availability for methyl-transfer reactions in epigenetic regulation and polyamine biosynthesis. It simultaneously reduces production of 1-methylnicotinamide (1-MNA) from nicotinamide — increasing nicotinamide availability as a NAD+ precursor. In adipose tissue (where NNMT is highly expressed), inhibition activates the polyamine flux pathway and shifts adipocytes toward a 'beige' phenotype with elevated energy expenditure. Epigenetic effects include changes to histone methylation status at genes governing fat cell differentiation.
Preclinical studies in obese mouse models showed that NNMT inhibition with 5-Amino-1MQ reduced adipocyte size and body weight without changes to food intake, suggesting effects on energy expenditure rather than appetite. Research is ongoing in metabolic syndrome, lipid metabolism, NAD+ biology, and epigenetic regulation of adipogenesis.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
